These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

793 related items for PubMed ID: 22949935

  • 1. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD, Nassar A, Siddiqui MT, Cohen C.
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [Abstract] [Full Text] [Related]

  • 2. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM, Harhay MO, Zhang P, Ugras S.
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [Abstract] [Full Text] [Related]

  • 3. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.
    Asian Pac J Cancer Prev; 2012 Nov; 13(8):4119-23. PubMed ID: 23098527
    [Abstract] [Full Text] [Related]

  • 4. Reliability of receptor assessment on core needle biopsy in breast cancer patients.
    Seferina SC, Nap M, van den Berkmortel F, Wals J, Voogd AC, Tjan-Heijnen VC.
    Tumour Biol; 2013 Apr; 34(2):987-94. PubMed ID: 23269610
    [Abstract] [Full Text] [Related]

  • 5. [Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].
    Zheng S, Zhang BL, Xiao T, Zou SM, Xue LY, Luo W, Guo L, Liu XY, Lü N.
    Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):465-70. PubMed ID: 22088373
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN.
    Asian Pac J Cancer Prev; 2014 Jul; 15(19):8395-400. PubMed ID: 25339035
    [Abstract] [Full Text] [Related]

  • 7. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
    Gahlaut R, Bennett A, Fatayer H, Dall BJ, Sharma N, Velikova G, Perren T, Dodwell D, Lansdown M, Shaaban AM.
    Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
    [Abstract] [Full Text] [Related]

  • 8. Triple-Positive Breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy.
    Zeng J, Edelweiss M, Ross DS, Xu B, Moo TA, Brogi E, D'Alfonso TM.
    Arch Pathol Lab Med; 2021 Jun 01; 145(6):728-735. PubMed ID: 33112958
    [Abstract] [Full Text] [Related]

  • 9. [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
    Yin HF, Wang YH, Qin XQ, Zhang H, Li T, Ye JM, Liu YH.
    Zhonghua Zhong Liu Za Zhi; 2009 Nov 01; 31(11):858-62. PubMed ID: 20137353
    [Abstract] [Full Text] [Related]

  • 10. Association of estrogen receptor, progesterone receptor and HER2 following neoadjuvant systemic treatment in breast cancer patients undergoing surgery.
    Tsai YM, Hsu HM, Chen CJ, Hsu KF, Fan HL, Chang H, Chan DC, Yu JC.
    Ir J Med Sci; 2014 Mar 01; 183(1):71-5. PubMed ID: 23757214
    [Abstract] [Full Text] [Related]

  • 11. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer.
    Yang YF, Liao YY, Li LQ, Xie SR, Xie YF, Peng NF.
    Pathol Res Pract; 2013 Dec 01; 209(12):797-802. PubMed ID: 24183366
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.
    Liu J, Deng H, Jia W, Zeng Y, Rao N, Li S, Jin L, Wu J, Song E, Su F.
    J Cancer Res Clin Oncol; 2012 May 01; 138(5):837-42. PubMed ID: 22290394
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Krystel-Whittemore M, Xu J, Brogi E, Ventura K, Patil S, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY.
    Breast Cancer Res Treat; 2019 Aug 01; 177(1):61-66. PubMed ID: 31144151
    [Abstract] [Full Text] [Related]

  • 16. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J, Piscuoglio S, Aggarwal G, Magda J, Friedlander MA, Murray M, Akram M, Reis-Filho JS, Weigelt B, Edelweiss M.
    Cancer Cytopathol; 2020 Feb 01; 128(2):133-145. PubMed ID: 31883437
    [Abstract] [Full Text] [Related]

  • 17. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T, Harano K, Masuda H, Kida K, Hess KR, Wang Y, Dirix L, Van Laere SJ, Lucci A, Krishnamurthy S, Woodward WA, Layman RM, Bertucci F, Ueno NT.
    BMC Cancer; 2020 May 18; 20(1):430. PubMed ID: 32423453
    [Abstract] [Full Text] [Related]

  • 18. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
    Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT.
    Ann Surg Oncol; 2010 Sep 18; 17(9):2411-8. PubMed ID: 20373039
    [Abstract] [Full Text] [Related]

  • 19. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA, Pilewskie M, Patil S, Barrio AV, Stempel M, Wen HY, Morrow M.
    Ann Surg Oncol; 2017 Sep 18; 24(9):2556-2562. PubMed ID: 28560596
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.
    Breast Cancer; 2015 May 18; 22(3):292-9. PubMed ID: 23749689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.